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We evaluated the hemodynamic pattern and the contribution of the
sympathetic nervous system in conscious and anesthetized (1.4 g/kg
urethane, iv) Wistar rats with L-NAME-induced hypertension (20 mg/
kg daily). The basal hemodynamic profile was similar for hyperten-
sive animals, conscious (N = 12) or anesthetized (N = 12) treated with
L-NAME for 2 or 7 days: increase of total peripheral resistance
associated with a decrease of cardiac output (CO) compared to normo-
tensive animals, conscious (N = 14) or anesthetized (N = 14). Sympa-
thetic blockade with hexamethonium essentially caused a decrease in
total peripheral resistance in hypertensive animals (conscious, 2 days:
from (means ± SEM) 2.47 ± 0.08 to 2.14 ± 0.07; conscious, 7 days:
from 2.85 ± 0.13 to 2.07 ± 0.33; anesthetized, 2 days: from 3.00 ± 0.09
to 1.83 ± 0.25 and anesthetized, 7 days: from 3.56 ± 0.11 to 1.53 ± 0.10
mmHg mL-1 min-1) with no change in CO in either group. However, in
the normotensive group a fall in CO (conscious: from 125 ± 4.5 to 96
± 4; anesthetized: from 118 ± 1.5 to 104 ± 5.5 mL/min) was observed.
The responses after hexamethonium were more prominent in the
hypertensive anesthetized group. However, no difference was ob-
served between conscious and anesthetized normotensive rats in
response to sympathetic blockade. The present study shows that the
vasoconstriction in response to L-NAME was mediated by the sympa-
thetic drive. The sympathetic tone plays an important role in the
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Introduction
The importance of the sympathetic ner-
vous system (SNS) during the evolution of
arterial hypertension depends on the specific
origin and phase of the hypertensive state.
Although an increase in SNS activity has
been reported in different models of hyper-
tension, controversy remains regarding the
importance of this mechanism in the genera-
tion and maintenance of hypertension (1,2).
The controversy regarding the role of the
SNS in the pathogenesis of hypertension
may be related in part to methodological
aspects such as type and/or phase of the
experimental model of hypertension and the
use of anesthetized animals. In rats, for ex-
ample, acute or chronic nitric oxide (NO)
synthase (NOS) inhibition by NG-nitro-L-
arginine methyl ester (L-NAME) causes an
increase in blood pressure (3,4). However,
the underlying mechanisms mediating hy-
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pertension are incompletely understood. This
model has an interesting feature: apparently
the sympathetic drive plays a more impor-
tant role in the chronic than in the early
phase of L-NAME hypertension (5-8).
Previous studies have provided compel-
ling evidence that chronic L-NAME-induced
hypertension is caused by widespread vaso-
constriction associated with a decrease in
cardiac output (CO) (9-12). Most of the stud-
ies were performed on anesthetized rats and
an important question is whether these data
can be extrapolated to the conscious state
during the evolution of hypertension. In con-
scious rats, acute intravenous infusion of L-
NMMA causes a much smaller increase in
blood pressure than in anesthetized rats (13).
In addition, acute hypertension induced by
L-NMMA in conscious humans was accom-
panied by a decrease in sympathetic nerve
activity (14). In contrast, in rats, after one
week of L-NAME treatment, the hyperten-
sion was completely reversed by acute sym-
pathetic ganglionic blockade (15).
The purpose of the present study was to
re-evaluate the hypothesis that sympathetic
activation contributes to maintaining but not
to initiating the vasoconstriction and hyper-
tension induced by inhibition of NO synthe-
sis. We evaluated the importance of the sym-
pathetic drive in the hemodynamic responses
(changes in peripheral resistance and CO in
response to acute ganglionic blockade) of L-
NAME-treated rats in two different phases
of the evolution of hypertension. Since anes-
thesia may be a limiting factor in the study,
conscious and anesthetized rats were evalu-
ated.
Material and Methods
Animals were provided by the Central
Animal House of the Federal University of
São Paulo, Escola Paulista de Medicina. The
experiments were approved by the Animal
Experimental Ethics Committee of the Fe-
deral University of São Paulo - Escola Pau-
lista de Medicina (Process No. 1536/04).
To obtain L-NAME-induced hyperten-
sion (Sigma-Aldrich, St. Louis, MO, USA),
male Wistar rats (230-280 g) were treated
orally by gavage with L-NAME (20 mg/kg,
daily) for 2 or 7 days. Normotensive rats
were used as controls. Upon arrival, the rats
were randomly assigned to one of these
groups according to treatment, i.e., normo-
tensive animals or animals with hyperten-
sion induced by L-NAME treatment for 2 or
7 days. The experiments were performed in
a group of conscious rats and in a group of
rats under anesthesia.
In the anesthetized group, rats were anes-
thetized 24 h before the experiment with
ketamine and xylazine (40 and 20 mg/kg, ip,
respectively) and instrumented with femoral
venous and arterial catheters for drug injec-
tion and arterial pressure recording, respec-
tively. Catheters were externalized through
the neck.
On the next day, arterial pressure and heart
rate (HR) were recorded in awake, freely mov-
ing rats, and the animals were then gradually
anesthetized with a maximum dose of 1.4 g/kg
urethane, iv, over a period of approximately
1 h to avoid any change in basal arterial pres-
sure in response to anesthesia. The adequacy
of the anesthetic was ascertained by the lack
of a dodge reaction to hind paw pinching and
by pupil diameter. Additional anesthesia (5%
of the initial dose) was administered when
necessary.
The trachea was cannulated for sponta-
neous ventilation with oxygen-enriched air
(with a gas mixture of 100% O2 and room
air), and pulsatile arterial pressure was re-
corded with a P23XL transducer (Statham
Instruments Division, Gould Inc., Cleveland,
OH, USA) connected to a Biopac system
(MP 100 workstation for PC). Mean arterial
pressure (MAP) and HR were obtained from
the arterial pressure signal. Rectal tempera-
ture was maintained at 37 ± 0.5ºC by means
of a servo-controlled electric blanket.
CO was estimated by thermodilution us-
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ing the Cardiomax III system (Columbus
Instruments Inc., Columbus, OH, USA). This
method is based on the principles of dilution
and uses a known quantity of cold solution
injected into the bloodstream to create a
thermal deficit as a variant of the indicator-
dilution method. Thus, a bolus of 100 µL
saline was injected in the right atrium through
a catheter inserted into the right jugular vein.
The changes in temperature were sensed by
a thermistor positioned in the aortic arch
introduced through the right carotid artery.
A curve showing the change in temperature
over time was calculated by the Cardiomax
III system and converted into a measure-
ment of CO. Stroke volume (SV) was also
calculated by the Cardiomax III system, di-
viding CO by HR.
To determine the basal levels of the car-
diovascular parameters, three to four indi-
vidual measurements of CO were performed
over a period of 5 min and the basal value is
reported as the mean of these individual
values. The SNS tone was evaluated by acute
hexamethonium (Sigma-Aldrich) injection
(20 mg/kg, iv) and the measurements of
cardiovascular parameters were performed
when arterial pressure had reached a stable
level just after the ganglionic blockade. Ad-
ditional doses of hexamethonium (5 to 10
mg/kg, iv) did not cause any further decrease
in cardiovascular parameters in any group.
Total peripheral resistance (TPR) was
calculated by dividing MAP by CO and is
reported as mmHg mL-1 min-1.
Conscious rats were instrumented on the
day of the experiment in the same way as the
anesthetized rats (except for the trachea),
under 2% halothane anesthesia and the ex-
periments were performed at least 4 h after
the end of surgery, when the basal values of
cardiovascular parameters were considered
to be normal.
Statistical analysis
Data are reported as means ± SEM. The
significance of changes in MAP, CO, SV,
TPR, and HR was determined within each
group by the Student paired t-test. The car-
diovascular responses to microinjection of
hexamethonium in conscious and anesthe-
tized rats were assessed by one-way analysis
of variance followed by the Student-New-
man-Keuls test. Differences were consid-
ered to be significant for a P value <0.05.
Results
Hemodynamic pattern of L-NAME-treated
rats
Conscious rats. Rats treated with L-
NAME for 2 (L-NAME-2d, N = 6) and 7 (L-
NAME-7d, N = 6) days had a significant
increase in MAP (171 ± 3 and 161 ± 3
mmHg, respectively) compared to the con-
trol group (109 ± 2 mmHg).
The main characteristic of hypertensive
rats was a progressive statistically signifi-
cant increase in TPR (2.47 ± 0.08 and 2.85 ±
0.13 mmHg mL-1 min-1 for L-NAME-2d and
7d days, respectively) compared to the nor-
motensive group (0.92 ± 0.04 mmHg mL-1
min-1). On the other hand, there was a large
and progressive statistically significant de-
crease in CO (71 ± 2.5 and 59 ± 2 mL/min for
2 and 7 days, respectively) compared to
control (125 ± 4.5 mL/min). All values are
presented in Table 1.
Urethane-anesthetized rats. The main
characteristic of this group was a progres-
sive statistically significant increase in MAP
(L-NAME-2d: 153 ± 0.7 and L-NAME-7d:
166 ± 1.4 mmHg; N = 6 and 6, respectively),
compared to the normotensive control group
(116 ± 0.9 mmHg), as shown in Table 2. The
increase in MAP was also mediated by a
progressive and significant increase in TPR
(L-NAME-2d: 3.00 ± 0.09 and L-NAME-
7d: 3.56 ± 0.11 mmHg mL-1 min-1), with a
large decrease in CO (L-NAME-2d: 55 ± 1.7
and L-NAME-7d: 50 ± 1.7 mL/min) com-
pared to control group (TPR: 1.00 ± 0.02
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mmHg mL-1 min-1 and CO: 118 ± 1.5 mL/
min). CO decreased mainly due to SV reduc-
tion, as shown in Table 2. A significant
decrease in HR was also observed only in
the 2-day group, as shown in Table 2.
Comparison of conscious and anesthe-
tized rats. The L-NAME-2d conscious group
had a significantly higher basal CO (71 ± 2.5
mL/min) and MAP (171 ± 3 mmHg) com-
pared to anesthetized rats (CO: 55 ± 1.7 mL/
min; MAP: 153 ± 0.7 mmHg). On the other
hand, an increase in TPR was observed in
response to anesthesia (3.00 ± 0.09 for con-
scious rats and 2.47 ± 0.08 mmHg mL-1 min-1
for anesthetized rats). The low value found
for CO in anesthetized animals was possibly
due to a decrease in SV (135 ± 4.5 µL).
However, in the L-NAME-7d group, the
difference observed with anesthesia was less
evident than in the L-NAME-2d group; only
a significant increase in TPR was observed
(anesthetized 7-day-treated group: 3.56 ±
0.11; 2-day-treated conscious animals: 2.85
± 0.13 mmHg mL-1 min-1).
The increase in MAP in conscious rats
was maximum after 2 days of treatment. In
contrast, anesthetized rats showed a pro-
gressive statistically significant increase in
MAP between 2 and 7 days mediated by a
progressive statistically significant increase
in TPR. Although there was no change in
MAP between 2 and 7 days in conscious
rats, a significant decrease in CO associated
with an increase in TPR was observed, as
shown Table 1.
In normotensive rats, anesthesia did not
change the values of MAP, CO or TPR;
there was only a significant increase in the
basal level of HR, as shown in Table 2.
Hemodynamic responses to acute
sympathetic system blockade
Acute SNS blockade with hexametho-
nium produced a significant decrease in MAP
in all groups.
In conscious hypertensive animals, the
fall in MAP observed after hexamethonium
was mediated only by a decrease in TPR; no
changes in CO were observed in any group
(2 and 7 days), as shown in Figure 1. The
delta of the decrease in TPR after hexa-
methonium did not differ significantly be-
tween groups. However, the P value was
close to the level of significance (2 days:
0.45 ± 0.18, and 7 days: 0.77 ± 0.15 mmHg
mL-1 min-1, P < 0.1). Furthermore, the change
in MAP in response to sympathetic blockade
did not differ between the 2- and 7-day
groups (2 days: 32.18 ± 8.5 and 7 days:
46.10 ± 10 mmHg).
Table 2. Basal hemodynamic pattern of anesthetized rats with hypertension induced
by 2 days (2d) and 7 days (7d) of L-NAME treatment and of normotensive anesthetized
animals.
Anesthetized CO TPR (mmHg SV MAP HR
rats  (mL/min) mL-1 min-1) (µL) (mmHg) (bpm)
Control 118 ± 1.5 1.00 ± 0.02 262 ± 4.5 116 ± 0.9 454 ± 5.2
(N = 14)
L-NAME-2d 55 ± 1.7* 3.00 ± 0.09* 135 ± 4.5* 153 ± 0.7* 429 ± 4.5*
(N = 6)
L-NAME-7d 50 ± 1.7* 3.56 ± 0.11* 118 ± 2.8* 166 ± 1.4* 444 ± 3.3
(N = 6)
Data are reported as means ± SEM. The rats received 20 mg/kg L-NAME daily. CO =
cardiac output; TPR = total peripheral resistance; SV = stroke volume; MAP = mean
arterial pressure; HR = heart rate.
*P < 0.05 compared to the normotensive group (Student t-test).
Table 1. Basal hemodynamic pattern of conscious rats with hypertension induced by 2
days (2d) and 7 days (7d) of L-NAME treatment and of normotensive conscious
animals.
Conscious CO TPR (mmHg SV MAP HR
rats  (mL/min) mL-1 min-1) (µL) (mmHg) (bpm)
Control 125 ± 4.5 0.92 ± 0.04 316 ± 12.5 109 ± 2 396 ± 14
(N = 14)
L-NAME-2d 71 ± 2.5* 2.47 ± 0.08* 216 ± 5* 171 ± 3* 343 ± 8.5*
(N = 6)
L-NAME-7d 59 ± 2* 2.85 ± 0.13* 174 ± 7* 161 ± 3* 339 ± 11
(N = 6)
Data are reported as means ± SEM. The rats were treated with 20 mg/kg L-NAME
daily. CO = cardiac output; TPR = total peripheral resistance; SV = stroke volume;
MAP = mean arterial pressure; HR = heart rate.
*P < 0.05 compared to the normotensive group (Student t-test).
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In L-NAME-anesthetized hypertensive
rats, the decrease in MAP after sympathetic
blockade was more prominent 7 days (from
166 ± 1.4 to 78 ± 7.9 mmHg) than 2 days
after treatment (from 153 ± 0.7 to 88 ± 6.2
mmHg; Figure 1). The fall in MAP was also
mediated by a decrease in TPR in both groups.
Different from what was observed in con-
scious rats, there was a significant difference
between the 2- and 7-day groups regarding
the TPR variation in response to the sympa-
thetic blockade, with a larger decrease in the
7-day group (2 days: 1.17 ± 0.18 and 7 days:
2.02 ± 0.28 mmHg mL-1 min-1).
Comparison of conscious and anesthe-
tized animals showed that the fall in MAP
after hexamethonium was greater in anes-
thetized animals. The larger fall in MAP in
anesthetized rats was mediated by a decrease
in TPR, both in the 2-day group and in the 7-
day group. The basal level of TPR was in-
creased by anesthesia. In this case, the dif-
ference may have been related to the varia-
tion in the basal condition between groups.
These data are shown in Figure 1.
In normotensive control rats there was no
difference in the basal hemodynamic condi-
tion in response to anesthesia, as shown in
Tables 1 and 2. The SNS blockade caused a
decrease of MAP to acute spinal levels in
both anesthetized and conscious rats (from
116 ± 0.9 to 62 ± 1.8 for anesthetized rats
and from 109 ± 2 to 66 ± 3 mmHg for
conscious rats), as shown in Figure 1. In
addition, the change in MAP and TPR in
response to hexamethonium was more
marked in hypertensive than in normoten-
sive rats.
The decrease of MAP in response to SNS
blockade in the normotensive groups was
due to a decrease in TPR and CO in con-
scious and in anesthetized rats, as shown in
Figure 1. In this case, there was a differential
hemodynamic response to sympathetic
blockade by hypertensive and normotensive
animals. In hypertensive rats, the sympa-
thetic action was mainly on TPR, while in
normotensive rats TPR and CO were af-
fected.
Discussion
The new finding of the present study is
that in conscious L-NAME-treated rats sym-
pathetic activation appears in the initial phase
of the development of hypertension. The
sympathetic contribution to hypertension did
not differ between 2 and 7 days of treatment.
On the other hand, a time-dependent sympa-
thetic activation in response to L-NAME
Figure 1. Mean arterial pressure (MAP), total peripheral resistance (TPR) and cardiac
output (CO) before (open columns) and after (filled columns) administration of hexametho-
nium in the conscious (A) and anesthetized (B) condition for normotensive (normotensive,
N = 14 and 6, respectively), L-NAME 2 days (L-NAME-2d, N = 6 and 6, respectively) and L-
NAME 7 days (L-NAME-7d, N = 6 and 6, respectively) animals. *P < 0.05 for the compari-
son of before and after hexamethonium injection, +P < 0.05 for the difference between
normotensive and L-NAME groups before hexamethonium; #P < 0.05 for the comparison of
the normotensive and L-NAME groups after hexamethonium (one-way analysis of variance
followed by the Student-Newman-Keuls test).
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was observed in anesthetized rats. Further-
more, in both conscious and anesthetized
rats, the SNS plays a major role in the main-
tenance of L-NAME hypertension. Acute
sympathetic blockade caused a decrease in
CO and TPR in normotensive rats, while in
hypertensive rats only a decrease in TPR
was observed, indicating that hypertension
is caused by a sympathetically mediated va-
soconstriction.
Previous studies have provided evidence
that chronic L-NAME-induced hypertension
is not caused by an expanded plasma volume
but rather by widespread vasoconstriction
(16,17). However, those studies were per-
formed one week after NOS blockade and
therefore they did not answer the question of
whether the SNS plays an important role in
mediating vasoconstriction and hypertension
in the initial phase of NO inhibition.
Experiments in conscious instrumented
animals provide a straightforward approach
to this question. We found that in conscious
rats the hemodynamic pattern in response to
NO inhibition for 2 or 7 days was compa-
rable. More importantly, the vasodilatation
in response to sympathetic blockade was
similar in the two phases studied. Thus, our
results strongly suggest that L-NAME-in-
duced hypertension is sympathetically me-
diated, even in the initial stage. We chose to
study the contribution of the sympatheti-
cally mediated vasoconstriction in L-NAME-
treated animals 2 days after the beginning of
treatment in order to avoid a baroreceptor-
mediated compensatory action on sympa-
thetic activity. It has been demonstrated that
a chronically elevated level of arterial pres-
sure will “reset” the set-point of the reflex to
a higher operating point, such that some 48 h
after the onset of elevation the reflex output
will be back to its original level (18). In a
previous study it was reported that acute NO
blockade in baroreceptor-intact animals re-
duced sympathetic nerve activity. However,
after barodenervation an increase in sympa-
thetic nerve activity was observed (19). Taken
together, these results suggest that in the
initial phase the increase in the sympathetic
nerve activity mediated by NO synthesis
inhibition is compensated in part by barore-
ceptor activity.
The role of the SNS in L-NAME-in-
duced hypertension is still controversial.
Acute inhibition of the SNS in this model
has been shown to produce either a substan-
tial fall or a small change in blood pressure,
particularly in the initial phase of hyperten-
sion. However, a progressive increase in
sympathetic tone was reported by others (8,
20,21). This discrepancy may be related to
methodological reasons, such as the dose
and duration of L-NAME treatment and the
use of anesthesia. In the present study, we
found that in conscious rats sympathetic ac-
tivation is an important mechanism in the
early stage of L-NAME hypertension; a time-
dependent sympathetic activation was ob-
served only in anesthetized rats. The in vivo
assessment of the role of the SNS in cardio-
vascular regulation is a challenging proce-
dure. At the present time, there is no perfect
method to quantify sympathetic activity, es-
pecially over long periods of time and par-
ticularly to compare different subjects. In
the present study, we used acute hexametho-
nium bromide administration to measure
hemodynamic variables. Our laboratory and
others have used this technique to estimate
the sympathetic support of arterial pressure
(8,22). Although this is a valid technique, it
is only useful as an acute indicator of sympa-
thetic involvement, and one limitation of
this method is that it is not possible to differ-
entiate the effects of sympathetic nerve ac-
tivity blockade on different vascular beds. It
has been shown before that chronic block-
ade of NO may increase the vascular re-
sponse to sympathetic activation (23). How-
ever, it is not possible to discriminate be-
tween a possible increase in vascular reac-
tivity to catecholamines and an increase in
the central activation of the SNS with the
ganglionic blockade.
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Furthermore, the mechanisms that lead
to sympathetic activation during NO inhibi-
tion are not fully understood. There is a
possibility that central NO mechanisms are
involved in the control of sympathetic vaso-
motor activity. A number of studies have
provided evidence that NO is involved in
regulating sympathetic nervous activity
within the brain. For example, intravenous
injections of L-NAME increase arterial pres-
sure and renal sympathetic nerve activity
(19) and arterial pressure increased only when
the SNS was intact (24). However, the exact
mechanism of the increase in sympathetic
drive mediated by L-NAME is still contro-
versial. One possibility is that NO within the
paraventricular nucleus (PVN) of the hypo-
thalamus may serve as a physiological regu-
lator of the SNS. PVN neurons project to
several areas within the CNS involved in
cardiovascular regulation, including the soli-
tary tract nucleus, ventrolateral medulla and
spinal cord. Perfusion of PVN neurons with
NO-containing cerebrospinal fluid or micro-
injection of sodium nitroprusside into the
PVN has been shown to elicit a significant
reduction in arterial blood pressure (25).
Furthermore, it has been proposed that de-
creased NO input and/or abnormalities in
post-NO mechanisms within the PVN may
contribute to the increase in sympathetic
nerve activity commonly observed during
disease states such as heart failure and hy-
pertension (25).
There is a potential limitation of the pres-
ent study that needs to be addressed. We
used urethane as anesthesia, and it has been
demonstrated that urethane increases the cen-
tral drive to the adrenal medulla, leading to
the secretion of epinephrine (26). However,
when we compared the results of conscious
and anesthetized rats, differences in the in-
tensity of the responses to the sympathetic
blockade were found only in L-NAME-
treated anesthetized rats compared to con-
scious L-NAME-treated rats, but not in nor-
motensive anesthetized rats compared to
normotensive conscious rats. Yet, an inter-
action between L-NAME treatment and the
anesthetic cannot be excluded.
Recently, Augustyniak et al. (27) showed
that acute infusion of L-NAME caused renal
sympathetic activation in conscious animals
when the confounding influence of the sino-
aortic baroreceptors was eliminated after
barodenervation. These data support the idea
that acute L-NAME infusion induced sym-
pathetic activation in conscious animals.
In the present study, the hypertension in
response to NO blockade was associated
with an increase in TPR and a decrease in
CO. Recently, Charkoudian et al. (28)
showed a similar hemodynamic pattern in
humans in response to progressive NOS in-
hibition. They also showed that the hyper-
tension in response to acute NO inhibition
was significantly higher in individuals with
high resting muscle sympathetic nerve ac-
tivity (MSNA) compared to those with low
resting MSNA. This result suggests that im-
pairment of NO function can cause a greater
risk of hypertension in individuals with higher
MSNA compared to individuals with lower
baseline MSNA.
Finally, the present study demonstrated
that in conscious L-NAME-treated animals
the increase in arterial pressure mediated by
sympathetic vasoconstriction occurs from
the initial phase to the maintenance phase of
hypertension. However, a time-dependent
sympathetic activation was more evident in
anesthetized rats.
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